Literature DB >> 22495390

Changes in chemokine receptor expression of regulatory T cells after ex vivo culture.

Rikhia Chakraborty1, Cliona Rooney, Gianpietro Dotti, Barbara Savoldo.   

Abstract

By controlling and limiting inflammatory conditions, naturally occurring regulatory T cells (Tregs), defined as circulating CD4(+)CD25(bright)FoxP3(+) cells, play critical roles in maintaining tolerance and preventing autoimmunity and thus have tremendous potential for adoptive immunotherapy. Because they represent a scanty subset of the CD4(+) T-lymphocyte subset, several approaches have been developed to isolate and expand ex vivo polyclonal Tregs. However, one limitation of the functional analyses performed on these cultured Tregs is the incomplete characterization of their tissue-trafficking properties. As this aspect provides crucial information for their therapeutic effects, we have here explored the chemokine receptor expression profile and function of Tregs cultured ex vivo with validated expansion protocols. Our data show that ex vivo cultured Tregs retained the expression of CCR7 but dramatically downregulated CCR5 as compared with freshly isolated Tregs. The differential chemokine receptors expression pattern corroborated with their respective steady state messenger RNA expression and also with their migration toward specific chemokines. Our analyses suggest that ex vivo cultured Tregs may display impaired or suboptimal migration to the inflamed tissues releasing RANTES and MIP-1α chemokines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495390      PMCID: PMC3650839          DOI: 10.1097/CJI.0b013e318255adcc

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  24 in total

Review 1.  Chemokines and chemokine receptors in leukocyte trafficking.

Authors:  Timothy S Olson; Klaus Ley
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-07       Impact factor: 3.619

2.  In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures.

Authors:  Wayne R Godfrey; Ying G Ge; Darrin J Spoden; Bruce L Levine; Carl H June; Bruce R Blazar; Stephen B Porter
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

3.  CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes.

Authors:  M Hirao; N Onai; K Hiroishi; S C Watkins; K Matsushima; P D Robbins; M T Lotze; H Tahara
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

Review 4.  Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues.

Authors:  Lisa M Ebert; Patrick Schaerli; Bernhard Moser
Journal:  Mol Immunol       Date:  2004-11-23       Impact factor: 4.407

Review 5.  Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells.

Authors:  Jeffrey A Bluestone; Qizhi Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-20       Impact factor: 11.205

6.  Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells.

Authors:  Petra Hoffmann; Ruediger Eder; Leoni A Kunz-Schughart; Reinhard Andreesen; Matthias Edinger
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

7.  Regulation of CCR5 expression and MIP-1alpha production in CD4+ T cells from patients with rheumatoid arthritis.

Authors:  C R Wang; M F Liu
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

8.  T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

Authors:  Antonio Di Stasi; Biagio De Angelis; Cliona M Rooney; Lan Zhang; Aruna Mahendravada; Aaron E Foster; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti; Barbara Savoldo
Journal:  Blood       Date:  2009-04-17       Impact factor: 22.113

9.  Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes.

Authors:  P Loetscher; M Seitz; M Baggiolini; B Moser
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

10.  Suppressor T cells in human diseases.

Authors:  Clare Baecher-Allan; David A Hafler
Journal:  J Exp Med       Date:  2004-07-26       Impact factor: 14.307

View more
  6 in total

1.  Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease.

Authors:  Rikhia Chakraborty; Aruna Mahendravada; Serena K Perna; Cliona M Rooney; Helen E Heslop; Juan F Vera; Barbara Savoldo; Gianpietro Dotti
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

Review 2.  Promoting transplantation tolerance; adoptive regulatory T cell therapy.

Authors:  N Safinia; J Leech; M Hernandez-Fuentes; R Lechler; G Lombardi
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

3.  Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.

Authors:  Miha Koprivnikar Kranjc; Metka Novak; Richard G Pestell; Tamara T Lah
Journal:  Radiol Oncol       Date:  2019-11-20       Impact factor: 2.991

4.  Clinical Applications of Regulatory T cells in Adoptive Cell Therapies.

Authors:  Gregory P Marshall; Judit Cserny; Daniel J Perry; Wen-I Yeh; Howard R Seay; Ahmed G Elsayed; Amanda L Posgai; Todd M Brusko
Journal:  Cell Gene Ther Insights       Date:  2018-01

5.  C-X-C Motif Chemokine Ligand 9 and Its CXCR3 Receptor Are the Salt and Pepper for T Cells Trafficking in a Mouse Model of Gaucher Disease.

Authors:  Albert Frank Magnusen; Reena Rani; Mary Ashley McKay; Shelby Loraine Hatton; Tsitsi Carol Nyamajenjere; Daniel Nii Aryee Magnusen; Jörg Köhl; Gregory Alex Grabowski; Manoj Kumar Pandey
Journal:  Int J Mol Sci       Date:  2021-11-24       Impact factor: 5.923

Review 6.  CC chemokine receptor 5: the interface of host immunity and cancer.

Authors:  Carlos Eduardo Coral de Oliveira; Julie Massayo Maeda Oda; Roberta Losi Guembarovski; Karen Brajão de Oliveira; Carolina Batista Ariza; Jamil Soni Neto; Bruna Karina Banin Hirata; Maria Angelica Ehara Watanabe
Journal:  Dis Markers       Date:  2014-01-19       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.